Skip to main content
Equibles
MEDP logo

MEDP · Medpace Holdings, Inc. · Metrics

Track MEDP — free

Use MEDP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MEDP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$642.00 -20.48 (-3.09%) Earnings today
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$18.49B
Shares
27.91M
Volume · Oct 21 1.03M Avg daily vol (3M) 285.75K

MEDP metrics

101 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$662.48
Market cap
$18.49B

Price action

20 metrics
Price change (1W)
+7.4%
Price change (30D)
+5.1%
Price change (3M)
+25.4%
Price change (6M)
+30.3%
Price change (YTD)
+18.0%
Price change (1Y)
+21.4%
Trailing year
Price change (5Y)
+256.1%
52-week high
$662.48
52-week low
$393.42
Change from 52-week high
+0.0%
Change from 52-week low
+68.4%
Annualized volatility
44.5%
Annualized volatility (3M)
40.3%
Beta
0.7
RSI (14D)
68.2
Price vs SMA 50
+8.9%
Price vs SMA 200
+25.7%
Avg volume (3M)
285,738
Relative volume
3.6
Average dollar volume
$172.65M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
27.91M

Valuation

12 metrics
P / E (TTM)
38.9
Trailing earnings · reciprocal yield 2.6%
PEG ratio
1.0
EV / revenue
6.1×
reciprocal yield 16.5%
EV / EBITDA
—
EV / EBIT
28.9×
reciprocal yield 3.5%
P / sales
6.2×
reciprocal yield 16.0%
P / book
40.0
reciprocal yield 2.5%
FCF yield
4.1%
TTM · current market cap
Buyback yield
1.7%
P / FCF
24.6
reciprocal yield 4.1%
P / operating cash flow
23.1
reciprocal yield 4.3%
Earnings yield
2.8%

Historical valuation

8 metrics
P / E historical average (3Y)
32.4×
reciprocal yield 3.1%
P / E historical average (5Y)
32.1×
reciprocal yield 3.1%
EV / revenue historical average (3Y)
5.1×
reciprocal yield 19.5%
EV / revenue historical average (5Y)
5.0×
reciprocal yield 20.1%
EV / EBIT historical average (3Y)
25.8×
reciprocal yield 3.9%
EV / EBIT historical average (5Y)
25.7×
reciprocal yield 3.9%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.7%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-22
Last earnings
2026-07-23

Profitability

9 metrics
Gross margin
—
Operating margin
21.0%
Trailing 12 months
Net margin
17.7%
Gross profit (TTM)
—
Operating profit (TTM)
$583.40M
Net income (TTM)
$491.50M
Trailing 12 months
Diluted EPS (TTM)
$17.04
FCF margin
25.4%
Effective tax rate
17.9%

Per share

11 metrics
Revenue per diluted share (TTM)
$96.51
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$20.24
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$17.05
Operating cash flow per diluted share (TTM)
$26.11
Free cash flow per diluted share (TTM)
$24.50
Capital expenditures per diluted share (TTM)
$1.60
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.74
Book value per share
$16.18

Growth

11 metrics
Revenue growth YoY
+17.2%
Year over year
Net income growth YoY
+34.5%
Revenue (TTM)
$2.78B
Trailing 12 months
EPS growth YoY
+37.1%
Shares change YoY
-2.0%
Year over year · fewer shares
Revenue CAGR (3Y)
+20.1%
Revenue CAGR (5Y)
+22.3%
EPS CAGR (3Y)
+28.0%
EPS CAGR (5Y)
+31.8%
FCF CAGR (3Y)
+24.8%
FCF CAGR (5Y)
+24.6%

Quality

14 metrics
Return on equity
113.3%
Return on assets
23.9%
Debt / equity
0.0
Current ratio
0.7
EBITDA (TTM)
—
Free cash flow (TTM)
$706.69M
Quick ratio
0.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$502.69M
Latest balance sheet
Cash & equivalents
$502.69M
Total assets
$2.06B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$752.66M
Capital expenditures (TTM)
$45.97M
R&D (TTM)
—
SG&A (TTM)
$189.02M
Stock compensation (TTM)
$21.21M
R&D / revenue
—
Stock compensation / revenue
0.8%

Ownership (13F)

9 metrics
13F filers
704
13F filer change QoQ
-32
Institutional ownership
89.1%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
29.8%
Private-fund adviser ownership
28.5%
Active holders' share change QoQ
+2.1%
Holder tenure
18.0
Price vs estimated holder cost
+40.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
19.5%

Short interest

3 metrics
Short interest
5.7%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$208.47M
Insider-sentiment score
2 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1668397 CUSIP 58506Q109 13F (30d) 123 filings 120 filers Visit website Investor relations